Shares of Clinitech Laboratory were quoting at Rs 120.75 on the NSE, a premium of 25.78% compared with the issue price of Rs 96.
The scrip was listed at Rs 115, a premium of 19.79% over the initial public offer (IPO) price. The stock is currently frozen in its upper limit of 5% over its listing price.The counter hit a high of Rs 120.75 and a low of Rs 110. About 3.23 lakh shares of the company changed hands at the counter.
Clinitech Laboratory's IPO was subscribed 36.99 times. The issue opened for bidding on 25 July 2024 and it closed on 29 July 2024. The price of the IPO was fixed at Rs 96 per share.
The IPO comprised fresh issue of 6,02,400 equity shares. The promoter and promoter group shareholding diluted to 61.57% from 83.65% pre-issue.
The company intends to utilize the net proceeds for expansion of diagnostic centres and general corporate purpose.
Clinitech Laboratory is a diagnostic services company with 8 centers in Thane and Navi Mumbai. They offer over 150 types of medical tests, including blood work, immunology, and pathology. The company employs 85 people.
The company recorded revenue from operations of Rs 6.43 crore and net profit of Rs 0.37 crore for the period as on 31 March 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
